PROpel Study :Primary analysis of showed significant improvement rPFS with Abiraterone + Olaparib vs abiraterone + placebo irrespective of biomarker subgroups in 1L therapy mCRPC patients
RADICALS-HD Study: After post-operative RT after RP, 24 months ADT improved both time to salvage ADT and Metastasis Free Survival compared to 6 months ADT
KEYLINK Study: No rPFS or OS benefit reported for Pembrolizumab + Olaparib for previously treated, molecularly unselected mCRPC patients compared to novel hormonal agents
CABASTY Study: Cabazitaxel 16 mg/m2 q2w plus G-CSF significantly reduced grade 3 neutropenia in pre-treated elderly mCRPC patients compared to Cabazitaxel 25 mg/m2 q3w plus G-CSF
CYPIDES Phase-2 Study: Preliminary results for ODM-208 first in class, oral, non-steroidal, and selective inhibitor of CYP11A1 in heavily pre-treated mCRPC patients with AR LBD mutation.
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
